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Abstract
Synthetic cannabinoids are one of the most rapidly expanding classes of novel psychoactive substances found in
illegal markets. These substances have evolved to the point that many examples no longer fit with the traditional
cannabinoid classification system, where assignment of these compounds is difficult and ambiguous, leading to
inconsistencies in regard to their chemical structures. This and other drawbacks can result in misunderstandings
between forensic scientists and legal disciplines, complicating efforts toward improving the inadequacies of cur-
rent antidrug laws. After a critical review, we offer an updated yet simplified cannabinoid classification system
with the intention to facilitate interdisciplinary communication.
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Traditional ‘‘cannabinoids’’ or ‘‘phytocannabinoids’’ in-
clude at least 66 biologically active terpene phenolic com-
pounds, derivatives of two-substituted 5-amylresorcine,
that are found inCannabis sativa herb1,2 or are the prod-
ucts thereof such as herbal cannabis (‘‘marihuana’’), can-
nabis resin (‘‘hashish’’), and liquid cannabis (‘‘cannabis
oil’’).3 Their synthetic analogues capable of binding
to cannabinoid receptors4,5 are also generally referred
to as ‘‘cannabinoids.’’ The understanding of ‘‘cannabi-
noids’’ and their complex biological activities is tightly
connected with the search for new pharmacological
medicines, driven by their structure–activity relationship
with the cannabinoid receptors. From this point of view,
the meaning of the term ‘‘cannabinoid’’ relates to the ef-
fect on or the affinity to the cannabinoid receptors. Such
compounds could be divided into cannabimimetics pos-
sessing cannabinoid activity (agonists) and antagonists
capable of binding to cannabinoid receptors without
causing cannabinoid effects but blocking the receptors
for other compounds.4–6
From the chemical point of view, ‘‘cannabinoids’’
embrace a variety of diverse structures that served a
basis for a classification system that has become the
current standard in the beginning of the 21st century.
According to this classification system, cannabinoids
are divided into the following classes.5–7
1. Classical cannabinoids: derivatives of dibenzo-
pyran (Fig. 1), namely D9-tetrahydrocannabinol
(THC), its isomers, and its structurally related syn-
thetic analogues, for example, HU-210, prepared
in 1988.8
2. Nonclassical cannabinoids: synthetic derivatives
of cyclohexylphenol (or 3-arylcyclohexanole),
for example, CP 47,497 and CP 55,940 (Fig. 1),
synthesized by US Pfizer company.9–11
3. Hybrid cannabinoids: to this class, some com-
pounds that were modeled to combine structural
features of both classical and nonclassical canna-
binoids could be conventionally referred. A series
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of such compounds was prepared by the authors
of the articles.12–14 An example could be found as
AM-403015 in Figure 1.
4. Aminoalkylindoles: large class of compounds that
take origin from a series prepared in 1991,16 which
gave the name to the whole class, including phar-
macologically interesting WIN55,212-2 (Fig. 2).
Further development of this class of synthetic can-
nabinoids was conducted by J.W. Huffman and
A. Makriyannis laboratories, which prepared and
studied pharmacological activity of a large number
of 3-naphthoylindoles,17–22 3-phenylacetylindoles,23
3-benzoylindoles,24,25 and naphthylmethylindo-
les.26 The aminoalkylindole chemical class was sub-
divided into the following groups: naphthoylindoles
(A), phenylacetylindoles (B), benzoylindoles (C),
and naphthylmethylindoles (D) (Fig. 2). Unfortu-
nately, the first three groups were among the
most prevalent chemical structures found in ‘‘herb-
al’’ smoking mixtures that were first detected in
2004 and are still prevalent today.4–6,27–32
5. Eicosanoids: endocannabinoids and their syn-
thetic analogues. The primary endocannabi-
noids are the arachidonic acid derivatives
FIG. 1. Chemical structures of some classical, nonclassical, and hybrid cannabinoids.
FIG. 2. Chemical structure of aminoalkylindoles: naphthoylindoles (A), phenylacetylindoles (B),
benzoylindoles (C), and naphthylmethylindoles (D) (basic structural fragment of most compounds of the
class is highlighted in bold).
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N-arachidonoylethanolamine (anandamide; AEA)
or 2-arachidonoylglycerol (2-AG) (Fig. 3), discov-
ered in 1992–1995.33–35
6. Other cannabinoids: heterocyclic compounds that
are not attributed to a specific class based on small
number of compounds prepared or insufficient
understanding of activity. This class could be ex-
emplified by known groups such as diarylpyra-
zoles (e.g., SR141716A and SR144528)36,37 and
3-naphthoylpyrroles38,39 (Fig. 4).
This classification system was later expanded to in-
clude adamantoylindoles, cyclopropoylindoles, and
indolecarboxamides within the category of aminoalky-
lindoles.40 However, indazolecarboxamides, another
emerging group of synthetic cannabinoids in illegal
markets, were added to the category of ‘‘others’’ since
they technically do not fit within the general aminoal-
kylindole category despite differing from their indole
counterpart by only a single nitrogen atom.
One of the first representatives of the ‘‘adamantylin-
dole’’ group with the general formula J (Fig. 5), tested
for cannabinoid activity, was (adamantan-1-yl)-1-[(1-
methylpiperidin-2-ylmethyl)-1H-indol-3-yl]methanone
(AM-1248), prepared in A. Makriyannis laboratory.21
Emergence of the N-pentyl analogue of AM-1248
in the market of novel psychoactive substances
(NPSs)41,42 in 2010 prompted a sudden need for assess-
ment and cannabinoid classification since no data on
the synthesis or on cannabimimetic activity of the com-
pound were described in publicly available literature to
date. Biological activity of (adamantan-1-yl)(1-pentyl-
1H-indol-3-yl)methanone was published 2 years after
it appeared in the illegal market of NPSs43 and required
addition as a subcategory to the former classification
system.44
Derivatives of 3-(2,2,3,3-tetramethylcyclopropa-
necarbonyl)indole with general formula K (Fig. 5)
that were synthesized in Abbott Laboratories45–48
were combined into ‘‘cyclopropoylindoles’’ group. Rep-
resentatives of this group have first appeared as de-
signer drugs in Russia in summer of 2011.49
Syntheses and pharmacological properties of can-
nabinoids from indolecarboxamides (or indole-3-
carboxamides) group (structure L in Fig. 5) are
reported43,50,51; however, occurrence of most new
compounds of this group is due to the market of de-
signer drugs. The first representative of the group in
the illegal market of NPSs, N-adamantylamide of
1-pentylindole-3-carboxylic acid (structure L, R =
pentyl, R1 = 1-adamantyl in Fig. 5), was detected in
Japan in the end of 2011.52 Beginning from this
FIG. 3. N-Arachidonoylethanolamine (anandamide) (E) and 2-arachidonoylglycerol (F).
FIG. 4. Structures of SR141716A (G), SR144528 (H), and 3-naphthoylpyrroles (I).
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date, this group of cannabinoids grows constantly,
its structural diversity being determined by availabil-
ity of amines used for the synthesis. Representatives
of the group (structure L, R1 = 1-naphthyl,53–56
1-carbamoylalkyl,57,58 and 1-methoxycarbonylalkyl59
shown in Fig. 5) were identified in the products sold
in the illegal market of NPSs at present. To the same
group, amide derived from cyclic amine like (4-
methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone
(‘‘MEPIRAPIM’’)60 should be referred.
Modification of aminoalkylindoles consisting of
insertion of additional nitrogen atom in the indole
ring and replacing the ketone with a carboxamide
functional group leads to a new group of synthetic
cannabinoids, indazolecarboxamides (to be exact,
indazole-3-carboxamides, structure M in Fig. 5). A great
number of such compounds were prepared and tested
in Prof. A. Makriyannis Laboratory61 and by Pfizer,
Inc.62,63 The results published in these articles were ap-
plied to the synthesis of designer drugs that appeared in
the illegal NPSs market simultaneously with com-
pounds from indole-3-carboxamides group bearing
analogous substituents.52,54,57,58,64–74 The divergence
of these similar structures into separate classifications,
the overly specific ‘‘aminoalkylindoles’’ group and
‘‘other,’’ highlights the need for an alternative classifica-
tion system that is amenable to an ever expanding rep-
ertoire of cannabinoids.
With the onset of the ‘‘spice’’ cannabinoids in the il-
legal market of NPSs observed since 2011 and rapid ex-
pansion of the chemical adulterants in such products,
the traditional classification system has become insuffi-
cient as a means to categorize the structural diversity
driven by the illegal market of NPSs.44,75 These sub-
stances are often referred to as designer drugs based
on nefarious attempts to circumvent regulations
where an NPS is ‘‘designed’’ around existing legislation.
The ‘‘aminoalkylindole’’ structural class continues to
evolve in response to specific regulatory listings and
the listing of specific examples has proven to be insuf-
ficient due to a rapid NPS life-cycle that is a far more
efficient process than adapting new legislation. Hun-
dreds of cannabinoid NPSs have been detected over
the past decade and the currently used classification
system limits the vast majority of these substances to
the category of ‘‘aminoalkylindole’’ or ‘‘other.’’ Further-
more, the subject of synthetic cannabinoids is no longer
unique to scientific discussion but is now a topic of
concern from a legal and public health perspective.
For this reason, it is of particular importance that a
clear distinction is made between phytocannabinoids
and synthetic cannabinoids based on relative health
risks resulting from abuse and from their disparate reg-
ulations. In contrast to the current classification sys-
tem with seven categories based on structure alone,
we propose three general categories based on natural
occurrence with subcategories based on structure.
According to this newly proposed classification system,
cannabinoids are divided into the following classes.
Phytocannabinoids: Naturally occurring chemical
compounds that are derived from Cannabis sativa,
and related species of this plant are categorized as phy-
tocannabinoids.
Endocannabinoids: Naturally occurring chemical
compounds produced by living organisms that are as-
sociated with the cannabinoid receptors (CB1 and
CB2) or more generally considered part of the endo-
cannabinoid system.
Synthetic cannabinoids: Non-naturally occurring
chemical compounds that either affect the endocanna-
binoid system or that are structural analogues of an
endocannabinoid, phytocannabinoid, or other syn-
thetic cannabinoids.
1. Phytocannabinoids
1.1. Tricyclic terpinoids
1.2. Bicyclic terpenoids
1.3. Other
FIG. 5. Structures of adamantanecarbonylindoles ( J), cyclopropanecarbonylindoles (K), indole-3-
carboxamides (L), indazole-3-carboxamides (M), and indole-3-carboxylates (N).
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2. Endocannabinoids
2.1. AEA pathway
2.2. 2-AG pathway
2.3. Other eicosanoids
3. Synthetic cannabinoids
3.1. Phytocannabinoid-similar
3.1.1. Tricyclics
3.1.2. Bicyclics
3.1.3. Other
3.2. Endocannabinoid-related
3.2.1. Eicosanoid-similar
3.2.2. Endocannabinoid modulators
3.3. Indole-similar
3.3.1. Indoles
3.3.1.1. 3-Carbonylindoles
3.3.1.1.1. Naphthoylindoles
3.3.1.1.2. Phenylacetylindoles
3.3.1.1.3. Benzoylindoles
3.3.1.1.4. Cycloalkanecarbonylindoles
3.3.1.1.4.1. Adamantanecarbony-
lindoles
3.3.1.1.4.2. Cyclopropanecarbony-
lindoles
3.3.1.1.5. Indole-3-carboxamides
3.3.1.1.6. Indole-3-carboxylates
3.3.1.1.7. Others 3-carbonylindoles
3.3.2. Indazoles
3.3.2.1. 3-Carbonylindazoles
3.3.2.1.1. Naphthoylindazoles
3.3.2.1.2. Indazole-3-carboxamides
3.3.2.1.3. Indazole-3-carboxylates
3.3.3. Benzimidazoles
3.3.4.1. 2-Carbonylbenzimidazoles
3.3.4.1.1. 2-Naphthoylbenzimidazoles
3.3.4. Other azaindoles
3.4. Indenes
3.4.1. Naphthylmethylindenes
3.5. Pyrrole-similar
3.5.1. Pyrroles
3.5.1.1. 3-Naphthoylpyrroles
3.5.2. Pyrrazoles
3.5.2.1. Diarylpyrazoles
3.6. Carbazole-similar
3.7. Miscellaneous
The former ‘‘classical’’ cannabinoid designation
includes both the natural D9-THC and synthetically de-
rived HU-210 based on their characteristic ABC-
tricyclic terpenoid ring structure. Whereas in the new
system, HU-210, an early example of a spice adulterant
is categorized as a synthetic cannabinoid. Likewise,
the AC-bicyclic compounds cannabidiol and syntheti-
cally derived CP-55,940 would be categorized as
FIG. 7. Chemical structures of exemplary endocannabinoids.
FIG. 6. Chemical structures of exemplary phytocannabinoids.
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‘‘nonclassical’’ in the former system, whereas in the new
system based on occurrence, plant-based D9-THC and
cannabidiol are classified as phytocannabinoids and
subcategorized based on structure. Isotopically labeled
forms, although synthetically derived, are also catego-
rized as phytocannabinoids. Primary examples of the
ABC-tricyclic, AC-bicyclic, and ‘‘other’’ terpenoid sub-
categories of the phytocannabinoid class include D9-
THC, cannabidiol, and cannabigerol (Fig. 6).
Within the endocannabinoid category, the new clas-
sification system also designates inclusion based on
natural occurrence such as the primary natural ligands,
arachidonyl ethanolamide (anandamide, AEA) and 2-
arachidonyl glycerol (2-AG). Biosynthetic precursors
and other eicosanoids such as 5,8,11-eicosatrienoyl
(mead) ethanolamide,76 N-dihomo-c-linolenoyl ethanol-
amine,77 and N-docosatetraenoyl ethanolamine77 that
bind to the cannabinoid receptors also fall within this cat-
egory (Fig. 7). However, endocannabinoid modulators
such as URB-597, an inhibitor of the fatty acid amide hy-
drolase enzyme that is responsible for the degradation of
AEA, are categorized as synthetic cannabinoids.
Synthetic cannabinoids that are structurally related
to a phytocannabinoid-similar counterpart are desig-
nated to Section 3.1.1–3.1.3 corresponding to their ter-
penoid structure using the same ABC ring system
designations (Fig. 8). For example, the synthetic canna-
binoids HU-21078 and CP-47,497,79 both detected as
adulterants in herbal smoking mixtures, in this system,
FIG. 8. Chemical structures of exemplary phytocannabinoid-similar and endocannabinoid-related
synthetic cannabinoids.
FIG. 9. Chemical structures of exemplary
indole-similar synthetic cannabinoid
subcategories.
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are categorized using the same structural criteria as the
phytocannabinoids but segregated from their natural
counterparts.
A simplified approach to the general ‘‘aminoalkylin-
dole’’ category of synthetic cannabinoids is to replace
this terminology with language that is based on the cen-
tral pharmacophore with multiple, specific subtypes.
Pharmacophore models of synthetic cannabinoids have
been described80,81 and this concept and terminology
have been utilized for the purpose of assessment of struc-
tural similarity.81 It is the opinion of the authors that a
‘‘core’’ subunit of a three-component pharmacophore
model will most effectively provide logical subcategories
for the synthetic cannabinoids. With this approach,
the ‘‘indole-similar’’ core may be further divided into
pharmacophore-based groups that are similar aromatic
systems differing only by the presence of an additional
nitrogen heteroatom including indazoles, benzimid-
azoles,82 and other azaindoles (Fig. 9). It should be
noted that the examples provided in Figure 9 would be
categorized in the category of ‘‘other,’’ based on the for-
mer classification system that is dependent on an overly
specific ‘‘core’’ + ‘‘head group’’ pharmacophore require-
ment (i.e., naphthoylindoles) described in Figure 10. The
latter classification requirement is dependent only on the
core structure that cast a wider net on the diverse func-
tionality observed with synthetic cannabinoid designer
drugs. The ‘‘core’’ pharmacophore is the logical choice
to provide such a basis as more chemical diversity is ob-
served within the ‘‘head’’ and ‘‘tail’’ pharmacophores.
Although no exemplary compounds for Sections 3.4–
3.6 covering indenes, pyrroles, pyrrazoles, and carba-
zoles are provided in this discussion, the same logic
and rationale for a pharmacophore-based categorization
system may be applied.
It is quite understandable that in the view of constant
development of the chemistry of new synthetic canna-
binoids that any new suggested classification system
will inevitably require updating, including the determi-
nation of new and separate groups and classes. Never-
theless we believe that our suggested classification
adequately captures the structural diversity of synthetic
cannabinoids, thus improving their systematization. As
a result, this updated classification system could serve
practical basis for improvement of national and inter-
national legislations to put analogues of known syn-
thetic cannabinoids under control with the aim to
prevent their propagation as designer drugs.
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